Last updated: October 14, 2026
Trastuzumab has shifted from a high-margin originator biologic to a mature oncology platform facing sustained biosimilar erosion. Roche’s Herceptin revenue fell from approximately CHF 6.4 billion in 2019 to CHF 1.6 billion in 2024, while biosimilar versions expanded across the United States, Europe, and other regulated markets. Growth has moved toward subcutaneous delivery, combination regimens, HER2-low diagnostics, and lifecycle products such as Phesgo rather than intravenous Herceptin itself [1-6].
How large is the trastuzumab market?
Trastuzumab remains one of the largest commercial HER2-directed biologics, with demand across breast cancer, metastatic gastric cancer, and gastroesophageal junction cancer. The market includes the originator Herceptin, trastuzumab biosimilars, subcutaneous formulations, and fixed-dose combinations.
| Market segment |
Principal products |
Commercial position |
| Intravenous trastuzumab |
Herceptin, Ogivri, Kanjinti, Trazimera, Herzuma, Ontruzant |
Mature, highly price-sensitive market |
| Subcutaneous trastuzumab |
Herceptin SC outside the U.S.; Herceptin Hylecta in the U.S. |
Differentiated administration and hospital workflow |
| Trastuzumab plus pertuzumab |
Phesgo |
Roche lifecycle strategy and competitive defense |
| Trastuzumab deruxtecan |
Enhertu |
Separate antibody-drug conjugate with expanding HER2 indications |
| Biosimilar trastuzumab |
Multiple manufacturers |
Main source of price and volume pressure |
The addressable market is broader than originator Herceptin sales. Trastuzumab biosimilar revenue is distributed among several companies, and public filings do not provide a complete global total. Company-level sales therefore provide the clearest measure of the financial trajectory.
What was Roche’s Herceptin revenue trajectory?
Roche’s Herceptin sales declined sharply after biosimilar entry in the United States and Europe.
| Year |
Roche Herceptin sales |
Year-over-year direction |
| 2018 |
CHF 7.0 billion |
Pre-biosimilar U.S. erosion |
| 2019 |
CHF 6.4 billion |
U.S. biosimilars began launching |
| 2020 |
CHF 4.4 billion |
Rapid U.S. and European decline |
| 2021 |
CHF 3.4 billion |
Continued conversion to biosimilars |
| 2022 |
CHF 2.7 billion |
Mature erosion |
| 2023 |
CHF 2.0 billion |
Ongoing substitution |
| 2024 |
CHF 1.6 billion |
Originator market contraction |
Source: Roche annual reports and full-year financial releases [1-6].
From 2018 to 2024, Herceptin revenue declined by roughly 77%. The reduction reflects lower net prices, biosimilar substitution, loss of exclusivity, and migration to newer HER2-directed products. Roche has offset part of the decline through Perjeta, Phesgo, Kadcyla, and Enhertu-related growth, but those products do not restore Herceptin’s former economics on a product-for-product basis.
When did trastuzumab lose exclusivity?
The principal U.S. composition-of-matter patent covering trastuzumab expired in 2019 after patent-term adjustment. Roche’s broader patent position extended beyond the core molecule through formulation, manufacturing, dosing, and method-of-use claims.
The U.S. exclusivity sequence was:
| Milestone |
Date or period |
Commercial effect |
| FDA approval of Herceptin |
September 1998 |
Originator launch |
| Core U.S. patent expiry |
2019 |
Biosimilar launch barrier materially weakened |
| First U.S. trastuzumab biosimilar approvals |
2017-2018 |
Regulatory competition established |
| First U.S. biosimilar commercial launches |
2019 |
Price and share erosion accelerated |
| Pediatric exclusivity for certain products |
Product-specific |
Did not prevent broad biosimilar entry |
| Current market |
2024-2025 |
Multiple biosimilars and reduced originator pricing power |
The biologics regulatory framework does not use the small-molecule Orange Book system in the same way. Biologics are governed primarily through the Public Health Service Act and FDA’s Purple Book. Herceptin is therefore not an ordinary Orange Book small-molecule case. Patent disputes have generally involved the Biologics Price Competition and Innovation Act, patent disclosure, patent-listing strategy, and negotiated launch timing [7-9].
What biosimilars compete with Herceptin?
The FDA has approved several trastuzumab biosimilars for indications that overlap with Herceptin. Major U.S. products include:
| Biosimilar |
Sponsor or commercial company |
FDA approval timing |
| Ogivri |
Mylan, later Viatris |
2017 |
| Herzuma |
Celltrion Healthcare |
2018 |
| Kanjinti |
Amgen and Allergan, now part of AbbVie’s legacy portfolio |
2019 |
| Trazimera |
Pfizer |
2019 |
| Ontruzant |
Samsung Bioepis |
2019 |
| Additional products and market entrants |
Regional and global sponsors |
Product-specific |
FDA biosimilar approvals include breast cancer and gastric cancer indications, subject to the product’s approved labeling and extrapolation determinations [10-15].
Europe saw earlier and broader biosimilar uptake than the United States. The European Medicines Agency approved trastuzumab biosimilars before U.S. commercial entry, and national procurement systems enabled rapid substitution in several countries. The U.S. market has been more fragmented because of payer policy, physician preference, hospital contracting, buy-and-bill economics, and differing launch agreements.
How strong is the trastuzumab patent estate?
The molecule-level patent estate is no longer a durable barrier to competition. The remaining commercial value lies in secondary patents and execution.
Formulation and delivery patents
Roche has protected or commercialized differentiated delivery formats, including:
- Intravenous trastuzumab formulations.
- Subcutaneous Herceptin using recombinant human hyaluronidase.
- Herceptin Hylecta in the United States.
- Device, container, dosing, and administration claims.
- Combination regimens involving chemotherapy or other HER2 therapies.
These patents can affect a biosimilar’s route of administration without preventing competition through intravenous products. A subcutaneous formulation may have separate intellectual-property and regulatory requirements from an intravenous biosimilar.
Method-of-use patents
Method claims have covered HER2-positive breast cancer, metastatic disease, adjuvant treatment, gastric cancer, dosing schedules, and combinations. Their commercial value varies by claim scope and whether the indication is carved out of biosimilar labeling.
Skinny-label or indication carve-outs can reduce infringement exposure, but they do not eliminate prescription substitution in all clinical settings. Hospital protocols, payer formularies, and physician prescribing practices determine how effectively a biosimilar can avoid a patented indication.
Manufacturing and know-how
Trastuzumab manufacturing remains a technical barrier, but not an effective market-wide exclusivity barrier. Biosimilar developers must establish:
- A stable mammalian-cell production system.
- Comparable glycosylation and higher-order structure.
- Consistent potency and purity.
- Validated downstream purification.
- Commercial-scale supply reliability.
- Comparability across manufacturing changes.
Manufacturing know-how can raise development cost and constrain new entrants. It does not protect Roche from established biosimilar companies with biologics manufacturing infrastructure.
What is the FDA regulatory status of trastuzumab biosimilars?
Trastuzumab biosimilars are approved under the abbreviated 351(k) pathway. The FDA requires analytical similarity, a focused clinical development package, and evidence that there are no clinically meaningful differences from the reference product.
The principal regulatory distinction is between biosimilarity and interchangeability. Biosimilarity does not automatically establish pharmacy-level substitution. Interchangeable status requires additional evidence under FDA rules and is relevant to automatic substitution policies, particularly for products dispensed through retail channels. Most trastuzumab use occurs in hospitals and oncology clinics, where formulary management and procurement contracts often have greater commercial influence than automatic substitution laws [7,16].
Which companies are challenging Roche’s trastuzumab franchise?
The competitive field includes large pharmaceutical companies, specialist biosimilar developers, and vertically integrated manufacturers.
| Company |
Relevant competitive position |
| Pfizer |
Trazimera and established oncology distribution |
| Amgen |
Kanjinti and large-scale oncology contracting |
| Viatris |
Ogivri and biosimilar commercialization infrastructure |
| Celltrion |
Herzuma and a broader oncology biosimilar portfolio |
| Samsung Bioepis |
Ontruzant and biologics development capability |
| Biocon Biologics |
Global biosimilar manufacturing and commercial reach |
| Fresenius Kabi |
Oncology and hospital procurement presence in selected markets |
| Roche |
Herceptin, Herceptin Hylecta, Phesgo, Kadcyla, and broader HER2 portfolio |
The strongest challengers are companies that can combine regulatory approvals with dependable supply, payer access, hospital contracting, and oncology field support. Approval alone does not guarantee meaningful share.
What patent litigation and settlements affected trastuzumab?
Trastuzumab competition produced extensive patent litigation and settlement activity before and around U.S. biosimilar launches. Developers used the BPCIA patent-exchange process, declaratory actions, inter partes review strategies, and negotiated launch agreements.
The commercial pattern was consistent:
- Biosimilar sponsors challenged or negotiated around Roche patent positions.
- Roche asserted secondary patents covering formulation, dosing, manufacturing, or treatment methods.
- Settlements established launch dates before or around the full resolution of all patent claims.
- Multiple biosimilars entered the U.S. market during 2019-2020.
The practical result was delayed but not prevented competition. Settlement dates helped stage launches, while the number of approved products reduced the likelihood that a single competitor would control the market. Litigation status is product-specific and changes as patents expire, cases settle, or claims are dismissed.
How has biosimilar competition changed trastuzumab pricing?
Trastuzumab pricing has experienced three forms of pressure:
- Lower list and net prices for biosimilars.
- Rebates and contracting discounts from the originator.
- Hospital and payer conversion toward lower-cost suppliers.
The U.S. provider economics are important. Many oncology drugs are purchased by hospitals and reimbursed under buy-and-bill systems. A biosimilar with a lower acquisition cost can gain share even when physician substitution is not automatic. Conversely, a product with weak supply, limited distribution, or poor contracting may lose share despite a low price.
Price erosion is usually gradual after the first launch and accelerates as multiple suppliers compete. Trastuzumab has enough approved suppliers to create sustained competition, but market concentration can remain high because hospitals value supply continuity and validated manufacturing.
How does trastuzumab compare with competing HER2 drugs?
| Product |
Modality |
Commercial role |
Effect on Herceptin |
| Herceptin |
Monoclonal antibody |
Original HER2 therapy |
Directly exposed to biosimilar erosion |
| Trastuzumab biosimilars |
Monoclonal antibodies |
Lower-cost substitutes |
Direct volume and price competition |
| Perjeta |
Pertuzumab antibody |
Combination treatment |
Expanded HER2 blockade and shifted regimen economics |
| Phesgo |
Pertuzumab plus trastuzumab with hyaluronidase |
Subcutaneous fixed-dose combination |
Retains Roche control over a delivery and combination platform |
| Kadcyla |
Trastuzumab emtansine ADC |
HER2-positive advanced disease |
Moves value into an antibody-drug conjugate |
| Enhertu |
Trastuzumab deruxtecan ADC |
Broadening HER2-directed oncology franchise |
Competes for clinical attention and Roche/partner revenue growth |
The key strategic change is migration from standalone trastuzumab to combination and antibody-drug conjugate regimens. Trastuzumab remains clinically foundational, but its standalone financial role has narrowed.
What is the outlook for trastuzumab revenue?
The originator outlook is continued decline in intravenous Herceptin revenue. The remaining revenue base is supported by:
- Countries with slower biosimilar adoption.
- Contracting advantages in selected hospital systems.
- Subcutaneous administration.
- Patients and providers retaining originator preference.
- Formulation and combination products.
- Markets where local regulatory or procurement rules delay substitution.
The principal downside risks are further net-price reductions, increased biosimilar interchangeability, tender losses, supply improvements by competitors, and treatment migration toward Phesgo or antibody-drug conjugates.
For biosimilar sponsors, the market remains commercially attractive but difficult. The opportunity is volume-based, and profitability depends on manufacturing scale, procurement access, portfolio breadth, and the ability to support oncology accounts. A late entrant faces limited pricing power unless it offers supply reliability, a differentiated route of administration, or access in underpenetrated geographies.
What generic launch scenarios exist for trastuzumab?
Trastuzumab is a biologic, so the relevant competitors are biosimilars rather than conventional generics.
| Scenario |
Expected market effect |
| Multiple biosimilars retain supply |
Persistent price competition and share fragmentation |
| One or two suppliers exit |
Reduced discounting and greater supply-risk premiums |
| Interchangeability expands |
Faster substitution in eligible channels |
| Roche concentrates on subcutaneous products |
Greater separation between IV and subcutaneous segments |
| New HER2 regimens displace monotherapy |
Long-term volume decline for all standalone trastuzumab products |
| Emerging markets adopt biosimilars rapidly |
Faster unit growth but lower realized prices |
What is the geographic coverage of trastuzumab competition?
The United States and Europe are the most developed biosimilar markets. Japan, South Korea, Canada, Australia, and several Latin American markets also have established trastuzumab competition. China and other emerging markets have expanded local biologics production and regulatory pathways, but pricing, reimbursement, and approval standards differ by jurisdiction.
Global revenue exposure is therefore uneven. Roche may retain stronger originator economics in countries with slower tendering or limited biosimilar penetration. In markets using centralized procurement, price competition can be severe once multiple products qualify.
Key Takeaways
- Roche Herceptin revenue fell from about CHF 7.0 billion in 2018 to CHF 1.6 billion in 2024.
- The core U.S. trastuzumab patent expired in 2019, enabling broad biosimilar entry.
- Major U.S. biosimilars include Ogivri, Herzuma, Kanjinti, Trazimera, and Ontruzant.
- Secondary formulation, delivery, method-of-use, and manufacturing patents delayed or shaped entry but did not preserve molecule-level exclusivity.
- Roche’s strategic defense is based on subcutaneous Herceptin, Phesgo, Kadcyla, Enhertu, and other HER2 products.
- The standalone trastuzumab market is mature and price-sensitive.
- Biosimilar success depends on contracting, supply reliability, manufacturing scale, and regulatory breadth.
- The most important long-term financial risk is migration from standalone trastuzumab to newer combination therapies and HER2 antibody-drug conjugates.
Frequently Asked Questions
Is trastuzumab still commercially important after biosimilar entry?
Yes. Trastuzumab remains widely used in HER2-positive breast and gastric cancers, but revenue has shifted from Roche’s originator product toward biosimilars and combination regimens.
Are trastuzumab biosimilars cheaper than Herceptin?
Usually. Net discounts vary by country, payer, hospital contract, and supplier. Competition is strongest where multiple biosimilars participate in centralized tenders.
Does Herceptin have patent protection for subcutaneous administration?
Subcutaneous trastuzumab products can rely on separate formulation, delivery, device, and combination patents. Those rights do not restore exclusivity for the intravenous molecule.
Can a trastuzumab biosimilar be automatically substituted for Herceptin?
Only products meeting applicable interchangeability requirements may qualify for automatic substitution under relevant U.S. rules. Hospital formulary decisions often control actual use.
Will trastuzumab revenue recover through newer HER2 products?
Roche can offset part of the decline through Phesgo, Kadcyla, and other HER2 products, but those products represent separate franchises rather than a direct recovery of Herceptin’s former revenue.
References
-
Roche. (2019). Annual report 2019. F. Hoffmann-La Roche Ltd.
-
Roche. (2020). Annual report 2020. F. Hoffmann-La Roche Ltd.
-
Roche. (2021). Annual report 2021. F. Hoffmann-La Roche Ltd.
-
Roche. (2022). Annual report 2022. F. Hoffmann-La Roche Ltd.
-
Roche. (2023). Annual report 2023. F. Hoffmann-La Roche Ltd.
-
Roche. (2025). Roche full-year results 2024. F. Hoffmann-La Roche Ltd.
-
U.S. Food and Drug Administration. (2024). Biologics price competition and innovation act. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
-
U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term extension guidance. U.S. Department of Commerce.
-
U.S. Food and Drug Administration. (2017). Ogivri prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2018). Herzuma prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2019). Kanjinti prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2019). Trazimera prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2019). Ontruzant prescribing information. U.S. Department of Health and Human Services.
-
European Medicines Agency. (2024). Trastuzumab biosimilar medicines. European Union.
-
U.S. Food and Drug Administration. (2024). Interchangeable biosimilars. U.S. Department of Health and Human Services.
